# PDE5A

## Overview
The PDE5A gene encodes the enzyme phosphodiesterase 5A, which is a critical regulator of cyclic guanosine monophosphate (cGMP) levels within cells. This enzyme belongs to the phosphodiesterase family, which is responsible for the hydrolysis of phosphodiester bonds in cyclic nucleotides, thereby modulating various physiological processes. Phosphodiesterase 5A is particularly significant in the context of vascular smooth muscle function, where it plays a pivotal role in the regulation of vascular tone and blood flow by modulating the nitric oxide (NO)/cGMP signaling pathway (Ahmed2021Phosphodiesterase; Gebska2011Phosphodiesterase5A). The enzyme's activity is finely regulated through mechanisms such as phosphorylation and interaction with other proteins, which are crucial for its involvement in processes like vasodilation and smooth muscle relaxation (Zhu2009Type; Wilson2017Distinct). Given its central role in these pathways, PDE5A is a target for therapeutic interventions, particularly in cardiovascular diseases and conditions associated with endothelial dysfunction (Gebska2011Phosphodiesterase5A).

## Structure
Phosphodiesterase 5A (PDE5A) is a multidomain protein involved in the hydrolysis of cyclic GMP. The primary structure of PDE5A consists of a sequence of amino acids encoded by the PDE5A gene, which is expressed in three isoforms: PDE5A1, PDE5A2, and PDE5A3. These isoforms share the same catalytic domain but differ in the length of their N-terminal regulatory regions (Ahmed2021Phosphodiesterase).

The secondary structure of PDE5A includes alpha-helices and beta-sheets. The catalytic domain is composed of three helical subdomains: an N-terminal cyclin-fold domain, a linker helical domain, and a C-terminal helical bundle domain. The active site is located in the C-terminal helical bundle domain (Sung2003Structure; Ahmed2021Phosphodiesterase).

The tertiary structure of PDE5A features a catalytic domain and regulatory GAF domains. The GAF domains, located in the N-terminal region, are involved in controlling the catalytic activity and dimerization of the protein. The GAFa domain binds cGMP allosterically, while the GAFb domain contributes to dimerization (Zoraghi2005Structural; Ahmed2021Phosphodiesterase).

PDE5A forms homodimers, representing its quaternary structure, which is significant for its regulatory functions (Zoraghi2005Structural). Common post-translational modifications include phosphorylation, which plays a role in the regulation of its activity (Zoraghi2005Structural).

## Function
Phosphodiesterase 5A (PDE5A) is an enzyme that plays a critical role in regulating cyclic guanosine monophosphate (cGMP) levels in cells, which is essential for smooth muscle relaxation and vascular homeostasis. In endothelial cells, PDE5A is localized to caveolae, specialized plasma membrane subdomains involved in signal transduction. This localization allows PDE5A to modulate the activity of endothelial nitric oxide synthase (NOS3), thereby influencing nitric oxide (NO) production and endothelium-dependent vasodilation (Gebska2011Phosphodiesterase5A).

PDE5A is also involved in the NO/cGMP/PKG signaling pathway, which is crucial for endothelium-mediated vasorelaxation. By hydrolyzing cGMP, PDE5A regulates vascular tone and maintains proper endothelial function (Gebska2011Phosphodiesterase5A). In human arterial smooth muscle cells, PDE5A forms part of a signaling complex that includes protein kinase G (PKG) and the inositol-1,4,5-trisphosphate receptor (IP3R), allowing for localized control of PDE5A activity and PKG-dependent inhibition of calcium release (Wilson2017Distinct).

The enzyme's activity is modulated by phosphorylation, which enhances its catalytic function and cGMP binding. This regulation is crucial for its role in cellular processes such as migration, proliferation, and angiogenesis (Zhu2009Type; Ahmed2021Phosphodiesterase).

## Clinical Significance
Mutations and alterations in the expression of the PDE5A gene have been implicated in various diseases and conditions. In pediatric adrenocortical tumors (ACTs), germline-inactivating variants in PDE5A, such as the nonsense variant p.Q860*, have been identified. These mutations are associated with significantly downregulated expression of PDE5A in tumor tissues compared to normal adrenal tissues, suggesting a potential role in tumorigenesis (Pinto2020Germline).

In the context of vascular diseases, PDE5A expression is significantly reduced in thoracic aortic aneurysms (TAAs), which may contribute to the development of these aneurysms. The regulation of PDE5A by NOTCH family proteins, particularly NOTCH1 and NOTCH3, has been observed, indicating complex regulatory mechanisms that could impact vascular health (Cesarini2019Regulation).

In thyroid cancer, specifically papillary thyroid carcinomas (PTCs), PDE5A is overexpressed, particularly in tumors with the BRAF V600E mutation. This overexpression is associated with reduced expression of thyroid-specific genes and may influence cancer cell proliferation and migration, suggesting potential therapeutic implications for PDE5 inhibitors in managing thyroid tumors (Sponziello2015PDE5).

Additionally, a polymorphism in PDE5A, specifically the E90K variant, has been shown to affect the response to sildenafil therapy in dogs with pulmonary hypertension, indicating that similar genetic variations could influence drug efficacy in humans (Ueda2019Effect).

## Interactions
Phosphodiesterase 5A (PDE5A) is involved in several critical interactions within cells, particularly in the context of vascular endothelial and smooth muscle cells. In endothelial cells, PDE5A is localized to caveolae, where it interacts with endothelial nitric oxide synthase (NOS3). This interaction forms part of a feedback loop that modulates NOS3 activity, influencing endothelium-dependent vasodilation. Inhibition of PDE5A enhances NOS3 activity, while overexpression of PDE5A reduces it (Gebska2011Phosphodiesterase5A).

In human arterial smooth muscle cells (HASMC), PDE5A forms distinct intracellular signaling compartments. It associates with the inositol 1,4,5-trisphosphate receptor (IP3R) and protein kinase G (PKG) at the endoplasmic reticulum, which allows for localized control of cGMP-dependent signaling. This association is crucial for the regulation of calcium transients and smooth muscle function. A specific fraction of PDE5A, associated with IP3R and PKG, shows unique sensitivity to PKG-mediated activation via phosphorylation at serine 102 (Wilson2017Distinct).

These interactions highlight PDE5A's role in modulating key signaling pathways related to vasodilation and smooth muscle relaxation, making it a target for therapeutic interventions in cardiovascular diseases.


## References


[1. (Zhu2009Type) Bing Zhu, Li Zhang, Mikhail Alexeyev, Diego F. Alvarez, Samuel J. Strada, and Troy Stevens. Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype. American Journal of Physiology-Lung Cellular and Molecular Physiology, 296(2):L220–L228, February 2009. URL: http://dx.doi.org/10.1152/ajplung.90474.2008, doi:10.1152/ajplung.90474.2008. This article has 24 citations.](https://doi.org/10.1152/ajplung.90474.2008)

[2. (Zoraghi2005Structural) Roya Zoraghi, Emmanuel P. Bessay, Jackie D. Corbin, and Sharron H. Francis. Structural and functional features in human pde5a1 regulatory domain that provide for allosteric cgmp binding, dimerization, and regulation. Journal of Biological Chemistry, 280(12):12051–12063, March 2005. URL: http://dx.doi.org/10.1074/JBC.M413611200, doi:10.1074/jbc.m413611200. This article has 147 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/JBC.M413611200)

[3. (Sung2003Structure) Byung-Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro, and Joong Myung Cho. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature, 425(6953):98–102, September 2003. URL: http://dx.doi.org/10.1038/nature01914, doi:10.1038/nature01914. This article has 220 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/nature01914)

[4. (Ueda2019Effect) Yu Ueda, Lynelle R. Johnson, Eric S. Ontiveros, Lance C. Visser, Catherine T. Gunther-Harrington, and Joshua A. Stern. Effect of a phosphodiesterase-5a (pde5a) gene polymorphism on response to sildenafil therapy in canine pulmonary hypertension. Scientific Reports, May 2019. URL: http://dx.doi.org/10.1038/s41598-019-43318-z, doi:10.1038/s41598-019-43318-z. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-019-43318-z)

[5. (Ahmed2021Phosphodiesterase) Wesam S. Ahmed, Anupriya M. Geethakumari, and Kabir H. Biswas. Phosphodiesterase 5 (pde5): structure-function regulation and therapeutic applications of inhibitors. Biomedicine &amp; Pharmacotherapy, 134:111128, February 2021. URL: http://dx.doi.org/10.1016/j.biopha.2020.111128, doi:10.1016/j.biopha.2020.111128. This article has 71 citations.](https://doi.org/10.1016/j.biopha.2020.111128)

[6. (Gebska2011Phosphodiesterase5A) M. A. Gebska, B. K. Stevenson, A. R. Hemnes, T. J. Bivalacqua, A. Haile, G. G. Hesketh, C. I. Murray, A. L. Zaiman, M. K. Halushka, N. Krongkaew, T. D. Strong, C. A. Cooke, H. El-Haddad, R. M. Tuder, D. E. Berkowitz, and H. C. Champion. Phosphodiesterase-5a (pde5a) is localized to the endothelial caveolae and modulates nos3 activity. Cardiovascular Research, 90(2):353–363, March 2011. URL: http://dx.doi.org/10.1093/cvr/cvq410, doi:10.1093/cvr/cvq410. This article has 35 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/cvr/cvq410)

[7. (Cesarini2019Regulation) Valeriana Cesarini, Calogera Pisano, Gabriele Rossi, Carmela Rita Balistreri, Flavia Botti, Giorgio Antonelli, Giovanni Ruvolo, Emmanuele A. Jannini, and Susanna Dolci. Regulation of pde5 expression in human aorta and thoracic aortic aneurysms. Scientific Reports, August 2019. URL: http://dx.doi.org/10.1038/s41598-019-48432-6, doi:10.1038/s41598-019-48432-6. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-019-48432-6)

[8. (Pinto2020Germline) Emilia Modolo Pinto, Fabio R. Faucz, Luana Z. Paza, Gang Wu, Elizabeth S. Fernandes, Jerome Bertherat, Constantine A. Stratakis, Enzo Lalli, Raul C. Ribeiro, Carlos Rodriguez-Galindo, Bonald C. Figueiredo, and Gerard P. Zambetti. Germline variants in phosphodiesterase genes and genetic predisposition to pediatric adrenocortical tumors. Cancers, 12(2):506, February 2020. URL: http://dx.doi.org/10.3390/cancers12020506, doi:10.3390/cancers12020506. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers12020506)

[9. (Sponziello2015PDE5) Marialuisa Sponziello, Antonella Verrienti, Francesca Rosignolo, Roberta Francesca De Rose, Valeria Pecce, Valentina Maggisano, Cosimo Durante, Stefania Bulotta, Giuseppe Damante, Laura Giacomelli, Cira Rosaria Tiziana Di Gioia, Sebastiano Filetti, Diego Russo, and Marilena Celano. Pde5 expression in human thyroid tumors and effects of pde5 inhibitors on growth and migration of cancer cells. Endocrine, 50(2):434–441, April 2015. URL: http://dx.doi.org/10.1007/s12020-015-0586-x, doi:10.1007/s12020-015-0586-x. This article has 52 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12020-015-0586-x)

[10. (Wilson2017Distinct) Lindsay S. Wilson, Manhong Guo, M. Bibiana Umana, and Donald H. Maurice. Distinct phosphodiesterase 5a-containing compartments allow selective regulation of cgmp-dependent signalling in human arterial smooth muscle cells. Cellular Signalling, 36:204–211, August 2017. URL: http://dx.doi.org/10.1016/j.cellsig.2017.04.019, doi:10.1016/j.cellsig.2017.04.019. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2017.04.019)